Please login to the form below

Not currently logged in
Email:
Password:
I have forgotten my password

diffuse large B-cell lymphoma

This page shows the latest diffuse large B-cell lymphoma news and features for those working in and with pharma, biotech and healthcare.

Celgene boosts CAR-T stake again with Bluebird Bio deal

Celgene boosts CAR-T stake again with Bluebird Bio deal

Celgene partnered with Bluebird on a portfolio of CAR-T candidates in 2013, and followed that up with a deal to zero in on B-cell maturation antigen (BCMA) two years ... That deal gave it rights to Juno’s lead CAR-T candidate JCAR017 (lisocabtagene

Latest news

  • Roche to buy cancer data firm Flatiron for $1.9bn Roche to buy cancer data firm Flatiron for $1.9bn

    Meanwhile, in 2017 Roche used GNS Healthcare’s REFS technology to analyse large volumes of proprietary data, such as electronic medical records and next-generation sequencing data, in the hope of ... unravelling the hidden drivers of cancer progression

  • Celgene reaches $9bn agreement to buy Juno Celgene reaches $9bn agreement to buy Juno

    March. The purchase gives it rights to Juno’s lead CAR-T candidate JCAR017 (lisocabtagene maraleucel), which is in early-stage testing for relapsed and/or refractory diffuse large B-cell ... There are some interesting wrinkles in the transaction.

  • Novartis gets speedy reviews for new Kymriah filings Novartis gets speedy reviews for new Kymriah filings

    In the US, the Swiss pharma firm gets a priority review for Kymriah (tisagenlecleucel) for the treatment of adults with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) who are ... light from the FDA and EMA last year for its Yescarta

  • CAR-T therapies show long-term benefits in lymphoma CAR-T therapies show long-term benefits in lymphoma

    tisagenlecleucel) in adults with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), helped laid to rest doubts that CAR-T can provide sustainable cancer responses. ... Meanwhile, Yescarta was approved by the FDA for B-cell lymphoma in October

  • Novartis files CAR-T therapy CTL109 in Europe Novartis files CAR-T therapy CTL109 in Europe

    as follow-up indication diffuse large B-cell lymphoma (DLBCL) which it submitted to the FDA last month. ... Kite was the first to file its new therapy in Europe, seeking approval in August for DLBCL, transformed follicular lymphoma (TFL), and primary

More from news
Approximately 1 fully matching, plus 44 partially matching documents found.

Latest Intelligence

  • Deal Watch January 2018

    The company switched focus to its JCAR017 programme and recently reported promising data in a pivotal trial for relapsed and/or refractory diffuse large B-cell lymphoma (DLBCL). ... DLBCL = diffuse large B-cell lymphoma. BTK = Bruton's Tyrosine Kinase.

  • Pharma deals in April 2015 Pharma deals in April 2015

    MEDI4736 is an immune checkpoint inhibitor which is targeted against programmed cell death (PD-L1). ... its SAR3419, an antibody-drug conjugate designed to treat diffuse large B-cell lymphoma (DLBCL) and other blood cancers.

  • Pharma deals during June 2014 Pharma deals during June 2014

    a deal with NanoString Technologies for the development of a companion diagnostic assay to support the development of Revlimid for treatment of Diffuse Large B-Cell Lymphoma at a more modest

  • Current development and marketing of biosimilar monoclonal antibodies in Latin America Current development and marketing of biosimilar monoclonal antibodies in Latin America

    NA. BC: Breast cancer; DLBCL: Diffuse large B-cell lymphoma; FL: Follycular Lymphoma; NA: Not applicable; NSCLC: Non-Small Cell Lung Cancer; RA: Rheumatoid Arthritis; TT: Technology transfer.

More from intelligence
Approximately 0 fully matching, plus 4 partially matching documents found.

Latest appointments

  • Celgene boosts CAR-T stake again with Bluebird Bio deal Celgene boosts CAR-T stake again with Bluebird Bio deal

    Celgene partnered with Bluebird on a portfolio of CAR-T candidates in 2013, and followed that up with a deal to zero in on B-cell maturation antigen (BCMA) two years ... That deal gave it rights to Juno’s lead CAR-T candidate JCAR017 (lisocabtagene

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Anthill Agency

Anthill is a specialist digital agency and a strategic partner for life science companies....

Latest intelligence

No incentive for a cure
The paradox of ‘cost-effective but unaffordable’ life-saving medicines...
Why heading online for scientific meetings can yield greater HCP engagement
Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...

Quick links

Infographics

Multimedia